^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Drug:Zydelig (idelalisib) (PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    09/18/2014
    Excerpt:
    Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment...
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    11/26/2020
    Excerpt:
    In later relapses, a non-ChT approach is recommended [III, C]...idelalisib in double-refractory cases only with anti-infectious prophylaxis (co-trimoxazole/acyclovir) and CMV monitoring.
    DOI:
    10.1016/j.annonc.2020.11.008
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Follicular Lymphoma: Second-line and subsequent therapy…Other recommended regimens…PI3K inhibitors (relapsed/refractory after 2 prior therapies)…Idelalisib